Trial Profile
A Phase IV Multicenter, Randomized, Open Label, Two-Period, Crossover Study in Patients With Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by the eRapid Nebulizer System
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jul 2016
Price :
$35
*
At a glance
- Drugs Dornase alfa (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech; Roche
- 28 Apr 2015 New trial record